SS Innovations International Inc. (NASDAQ: SSII) announced record first-quarter 2026 financial results, with revenue surging 116.8% year over year to $11.1 million, driven by accelerating adoption of its SSi Mantra surgical robotic system. The company reported gross profit of $5.3 million, up from $1.1 million in the same quarter last year, as the installed base of SSi Mantra systems reached 194 across 11 countries.
As of June 22, 2026, the cumulative number of multi-specialty procedures completed with the SSi Mantra totaled 11,719, including 612 cardiac procedures, 175 telesurgeries, and 212 pediatric surgeries. Approximately 2,100 physicians have been trained on the system, which has been used to perform over 170 different types of procedures. The company recently completed the world’s longest-distance robotic cardiac telesurgery, highlighting the remote surgery platform's capabilities.
During the quarter, SS Innovations obtained regulatory approvals in Sri Lanka, Kenya, Indonesia, and the Philippines, expanding its international market access. The company continues to pursue regulatory clearance in both the United States and Europe while strengthening its presence in emerging healthcare markets. For more information, visit SS Innovations.
The strong quarterly performance underscores the growing global demand for robotic-assisted surgery, particularly in underserved regions. Leaders in business and technology should note that SS Innovations is positioning itself as a key player in the surgical robotics market, with a focus on affordability and telesurgery capabilities that could democratize access to advanced surgical care. The expansion into emerging markets and the successful telesurgery demonstration suggest potential for significant disruption in how surgical expertise is delivered across borders.
For investors, the 116.8% revenue growth and expanding installed base signal strong commercial traction. However, the company still faces the challenge of gaining regulatory approval in the U.S. and Europe, which could unlock much larger markets. The cumulative procedure data, including 175 telesurgeries, indicates growing confidence in the technology's reliability and safety.
The company's strategy of targeting high-volume procedures in cardiology and multi-specialty applications could drive further adoption. As healthcare systems worldwide seek to improve surgical outcomes and efficiency, SS Innovations' platform offers a compelling value proposition. The news was disseminated by InvestorWire, a specialized communications platform. For disclaimers, see InvestorWire Disclaimer.
